Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Jiankang Yuan's profitability continues to strengthen, with net profit increasing by 25.52% in the first quarter. There are multiple highlights for future product realization.
Published Time：
2022-04-29
On the evening of April 24, Healthy Yuan officially disclosed its 2022 first-quarter report. During the reporting period, the company achieved operating revenue of 4.657 billion yuan, a year-on-year increase of 12.36%; net profit attributable to shareholders of listed companies reached 461 million yuan, a year-on-year increase of 25.52%; net cash flow from operating activities reached 872 million yuan, a year-on-year increase of 76.27%, and its sustainable profitability continued to strengthen.
According to the quarterly report, the company's chemical preparations achieved operating revenue of 2.737 billion yuan, a year-on-year increase of 24.54%; raw materials and intermediates achieved revenue of 1.406 billion yuan, a year-on-year increase of 14.90%. The biggest driver of Healthy Yuan's Q1 performance growth came from the stable growth in sales of major products in the company's key specialty areas. Among them, respiratory preparation products achieved revenue of 363 million yuan, a year-on-year increase of 324.90%.
Healthy Yuan Pharmaceutical Group, headquartered in Shenzhen, has currently built an innovative, high-barrier complex preparation R&D technology platform represented by inhalation administration, antibody technology, and sustained-release microspheres, and is actively deploying cutting-edge technologies such as AI drug molecular design, synthetic biology, and intelligent drug delivery systems. Among them, the respiratory preparation R&D platform has taken the lead in breaking through the international market monopoly and has become prominent. In recent years, Healthy Yuan has broken through the barriers of R&D, approval, and production, and the commercialization of its flagship products such as "Shutanlin," "Lishutong," and "Wushu" has accelerated, achieving impressive sales results and further consolidating Healthy Yuan's position as a "leading domestic inhalant preparation player." This has marked a milestone in the history of the development of high-end inhalant preparations in China.
At the online 2021 annual performance briefing held on April 18, Healthy Yuan interacted and communicated with investors regarding the specific situation of the company's operating results and financial indicators in 2021, and provided detailed responses to questions of common concern among investors within the scope permitted by information disclosure.
It is worth mentioning that the company provided a detailed introduction to investors' questions about the general progress of cost reduction and efficiency improvement projects and pipelines: At the end of 2020, the company and Lizhu Group established the Healthy Yuan Biopharmaceutical Research Institute, focusing on the research and development of green pharmaceutical intermediates, pharmaceutical industrial enzymes, and biochemical raw materials. In early 2021, the Healthy Yuan Biopharmaceutical Research Institute signed a strategic cooperation agreement with Tencent Quantum Laboratory to jointly promote the application of quantum computing + artificial intelligence in the research of microbial synthetic biology and related drugs.
The current main research ideas focus on the success rate and efficiency of R&D, starting with large varieties to quickly achieve cost reduction and efficiency improvement for existing large varieties. To date, the screening work for two key projects, Cephalosporin C and phenylalanine, has progressed smoothly: ① The Cephalosporin C project has screened nearly 20,000 strains, obtaining more than 1,000 high-yielding strains, and about 100 strains have undergone laboratory and pilot tests. ② Phenylalanine project: More than 100 strains have been screened. We expect to further reduce the production cost of products in the future.
According to the quarterly report, Healthy Yuan's new fundraising and investment projects involve new product R&D, expansion of the Haibin Pharmaceutical Pingshan Pharmaceutical Industrialization Base, and information platform construction. Among them, key investment in the R&D of inhalation preparations is an important product for the company's strategic layout in the respiratory drug market, which will add new profit points for the company and improve its comprehensive competitiveness in the pharmaceutical market. Currently, Healthy Yuan's key products such as tobramycin inhalation solution (the first), formoterol fumarate inhalation solution, and terbutaline sulfate nebulization inhalation solution have been submitted for production, and there are many highlights for subsequent new product launches.
Disclaimer: The market is risky, and investment decisions should be made cautiously! This article is for reference only and does not constitute a basis for trading.
Source: Daily Economic News
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.